Movement disorders emergencies: A review;Emergências em distúrbios do movimento: Uma revisão

Arquivos de Neuro-Psiquiatria

Volumn 70, Issue 6, 2012, Pages 453-461

  Munhoz, Renato P ^a,b   Moscovich, Mariana ^a   Araujo, Patrícia Dare ^a   Teive, Hélio A G ^b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Dyskinesias; Dystonia; Malignant hyperthermia; Movements disorders; Neuroleptic malignant syndrome; Serotonergic syndrome; Status dystonicus; Stiff person syndrome

Indexed keywords

AMANTADINE; AMPHETAMINE; AMPHOTERICIN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXTROMETHORPHAN; DIPHENHYDRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LEVODOPA; LITHIUM; MONOAMINE OXIDASE B INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ACUTE DRUG REACTION; ACUTE DYSTONIA; ACUTE PSYCHOSIS; BLEPHAROSPASM; BUCOLINGUAL CRISIS; CLINICAL FEATURE; COMORBIDITY; DEMOGRAPHY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DYSKINESIA; DYSTONIA; EMERGENCY CARE; HEMIBALLISM; HUMAN; HYPERPYREXIA; LARYNX DYSTONIA; MALIGNANT HYPERTHERMIA; MORBIDITY; MORTALITY; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; OCULOGYRIC CRISIS; OPISTHOTONUS; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PSEUDODYSTONIA; REVIEW; RISK FACTOR; SEROTONERGIC SYMPTOM; SEROTONERGIC SYNDROME; STATUS DYSTONICUS; STIFF MAN SYNDROME; TIC; TORTICOLLIS; WILSON DISEASE;

EID: 84862675274     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2012000600013     Document Type: Review

References (59)

1. Kipps CM, Fung VSC, Grattan-Smith P, de Moore GM, Morris JGL. Movement disorder emergencies. Mov Disord 2005;20:322-334.
2. Melamed E, Ziv I, Djaldetti R. Management of motor complications in advanced Parkinson's disease. Mov Disord 2007;22(Suppl):S379-384.
3. Dziewczapolski G, Menalled LB, Savino MT, Mora M, Stefano FJE, Gershanik O. Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the 'super-off' phenomenon. Mov Disord 1997;12:159-166.
4. Gershanik O, Lera G, Gomez Arevalo G. Clinical profile of parkinsonian patients with super off phenomenon. Neurology 1994;44:248.
5. Gunzler SA, Koudelka C, Carlson NE, Pavel M, Nutt JG. Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. Arch Neurol 2008;65:193-198.
6. Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat Disord 2003;9:S3-S9.
7. Gil-Navarro S, Grandas F. Dyskinesia-hyperpyrexia syndrome: another Parkinson's disease emergency. Mov Disord 2010;25:2691-2692.
8. Poston KL, Frucht SJ. Movement disorders emergencies. J Neurol 2008;255:S2-S13.
9. Sá DS, Teive HA, Troiano AR, Werneck LC. Parkinsonism associated with neurocysticercosis. Parkinsonism Relat Disord 2005;11:69-72.
10. Robottom BJ, Weiner WJ, Factor SA. Movement disorders emergencies part 1. Hypokinetic disorders. Arch Neurol 2011;68:567-572.
11. Tousi B. Movement disorder emergencies in the elderly: recognizing and treating an often-iatrogenic problem. Cleve Clin J Med 2008;75:449-457.
12. Fahn S. Medical treatment of dystonia. In: Tsui JKC, Calne DB (eds). Handbook of dystonia. New York: Marcel Dekker; 1995:317-328.
13. Fabiani G, Teive HA, Germiniani F, Sá D, Werneck LC. Clinical and therapeutical features in 135 patients with dystonia: experience of movement disorders unity of the Hospital de Clínicas of the Universidade Federal do Paraná. Arq Neuropsiquiatr 1999;57:610-614.
14. Casey DE. Neuroleptic-induced acute dystonia. In: Lang AE (Ed). Drug-Induced movement disorders. Mount Kisco: Futura Publishing Co; 1992:21-41.
15. Barreira R, Magaldi RB. Acute dystonia after use of bromopride in pediatric patients. Rev Paul Pediatr 2009;27:110-114.
16. Robottom BJ, Factor SA, Weiner WJ. Movement disorders emergencies part 2. Hyperkinetic disorders. Arch Neurol 2011;68:719-724.
17. Frucht SJ. Hyperkinetic movement disorders emergencies. American Academy of Neurology. Minneapolis: Sillabus; 2002.
18. Miyasaki JM, Lang AE. Treatment of drug-induced movement disorders. In: Kurlan R (Ed). Treatment of movement disorders. Philadelphia: Lippincott; 1995:429-474.
19. Levenson JL. Neuroleptic malignant syndrome. AM J Psychiatry 1985;142:113.
20. Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenic role for dopamine receptor blockade? Neurology 1981;31:132-137.
21. Moscovich M, Nóvak FT, Fernandes AF, et al. Neuroleptic malignant syndrome. Arq Neuropsiquiatr 2011;69:751-755.
22. Trollor JN, Chen X, Sachdev SP. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009;23:477-492.
23. Rosebush PI, Garside S, Mazurek MF. Recognizing neuroleptic malignant syndrome. CMAJ 2004;170:1645.
24. Berardi D, Dell'Atti M, Amore M, De Ronchi D, Ferrari G. Clinical risk factors for neuroleptic malignant syndrome. Hum Psychopharmacol 2002;17:99-102.
25. Levinson DF, Simpson G. Sequelae of neuroleptic malignant syndrome. Biol Psychiatry 1987;22:273-278.
26. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrole and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 1991;159:709-712.
27. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aus N Z J Psychiatry 1999;33:650-659.
28. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-713.
29. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352:1112-1120.
30. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997;17:208-221.
31. Munhoz RP. Serotonin syndrome Induced by a combination of bupropion and SSRIs. Clin Neuropharmacol 2004;27:219-222.
32. Turkel SB, Nadala JG, Wincor MZ. Possible serotonin syndrome in association with 5-HT(3) antagonist agents. Psychosomatics 2001;42:258-260.
33. Ables AZ, Nagubilli R. Prevention, recognition, and management of serotonin syndrome. Am Fam Physician 2010;81:1139-1142.
34. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003;96:635-642.
35. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998;16:615-619.
36. Saidman W, Havard ES, Eger EI. Hyperthermia during anesthesia. JAMA 1964;190:1029-1032.
37. Ali SZ, Taguchi A, Rosenberg H. Malignant hyperthermia. Best Pract Res Clin Anaesthesiol 2003;17:519-533.
38. Mathews KD, Moore SA. Multiminicore myopathy, central core disease, malignant hyperthermia susceptibility, and RYR1 mutations: one disease with many faces? Arch Neurol 2004;61:27-29
39. Jankovic J, Penn AS. Severe dystonia and myoglobinuria. Neurology 1982;32:1195-1197.
40. Mariotti P, Fasano A, Contrarino MF, et al. Management of status dystonicus: our experience and review of the literature. Mov Disord 2007;22:963-968.
41. Manji H, Howard RS, Miller DH, et al. Status dystonicus: the syndrome and its management. Brain 1998;121:243-252
42. Teive HA, Munhoz RP, Souza MM, et al. Status dystonicus: study of five cases. Arq Neuropsiquiatr 2005;63:26-29.
43. Teive HA, Sá DS, Grande CV, Antoniuk A, Werneck LC. Bilateral pallidotomy for generalized dystonia. Arq Neuropsiquiatr 2001; 59:353-357.
44. Spitz M, Gonçalves L, Silveira L, Barbosa ER. Myelopathy as a complication of cervical dystonia. Mov Disord 2006;21:726-735.
45. Krauss JK, Jankovic J. Severe motor tics causing cervical myelopathy in Tourettés syndrome. Mov Disord 1996;11:563-566.
46. Shannon KM. Ballism. In: Jankovic J, Tolosa E (Eds). Parkinson's disease and movement disorders. 3 ed., Baltimore: Williams and Wilkins; 1998:365-375.
47. Coral P, Teive HAG, Werneck LC. Hemibalismo: relato de oito casos. Arq Neuropsiquiatr 2000;58:698-703.
48. Dewey RB, Jankovic J. Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol 1989;46:862-867.
49. Whittier JR. Ballism and the subthalamic nucleus (nucleus hypothalamicus; corpus Luysi) review of the literature and study of 30 cases. Arch Neurol Psychiatry 1947;58:672-692.
50. Lang AE. Persistent hemiballismus with lesions outside the subthalamic nucleus. Can J Neurol Sci 1985;12:125-128.
51. Lin JJ, Chang MK. Hemiballism-hemichorea and non-ketotic hyperglycemia. J Neurol Neurosurg Psychiatry 1994;57:748-750.
52. Lee BC, Hwang SH, Chang GY. Hemiballismus-hemochorea in older women: A clinical syndrome with MRI correlation. Neurology 1999;52:646-648.
53. Mestre TA, Ferreira JJ, Pimentel J. Putaminal petechial haemorrahage as the cause of non-ketotic hyperglycaemic chorea: a neuropathological case correlated with MRI findings. J Neurol Neurosurg Psychiatry 2007;78:549-550.
54. Zétola VF, Verschoor B, Lima FM, et al. Hemibalismo-hemicoréia em estado hiperglicêmico não cetótico: distúrbio do movimento associado ao diabete melito. Arq Bras Endocrinol Metab 2010;54:335-338.
55. Sethi KD, Patel BP. Inconsistent response to divalproex sodium in hemichorea/hemiballism. Neurology 1990;40:1630-1631.
56. Espay AJ, Chen R. Rigidity and spasms from autoimmune encephalomyelopathies: stiff-person syndrome. Muscle Nerve 2006;34:677-690.
57. Munhoz RP, Fameli H, Teive HA. Stiff person syndrome as the initial manifestation of systemic lupus erythematosus. Mov Disord 2010;25:516-517.
58. Brown P, Marsden CD. The stiff man and stiff man plus syndromes. J Neurol 1999;246:648-652.
59. Bhati MT, Datto CJ, O'Reardon JP. Clinical manifestations, diagnosis, and empirical treatments for catatonia. Psychiatry 2007;4:46-52.